RK-33

News alerts, weekly reports and conference planners

Company:

Natsar Pharma

Drug class:

DDX3 inhibitor

‹

›

BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	PARP inhibitor + RK-33 Sensitive: D – Preclinical PARP inhibitor + RK-33 Sensitive : D	PARP inhibitor + RK-33 Sensitive: D – Preclinical PARP inhibitor + RK-33 Sensitive : D
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	PARP inhibitor + RK-33 Sensitive: D – Preclinical PARP inhibitor + RK-33 Sensitive : D	PARP inhibitor + RK-33 Sensitive: D – Preclinical PARP inhibitor + RK-33 Sensitive : D

Associations
(2)